Clinical Benefit of Entrectinib for Patients With Metastatic Pancreatic Cancer

Michael Pishvaian, MD, PhD, director, Phase I Clinical Program, co-director of the Ruesch Center Pancreatic Cancer Program Medical Oncology, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, Georgetown University Lombardi Comprehensive Cancer Center, discusses the results of a study investigating entrectinib in patients with metastatic pancreatic cancer who harbor NTRK and ROS1 fusions.

Entrectinib was given to 2 patients with NTRK fusions and 1 patient with a ROS1 fusion and was well tolerated. All of the patients maintained a high level of quality of life while on the study. Two of the patients experienced a response and long-term stabilization of their disease.

Though this was a small subgroup of patients, the drug looked very promising, and there was a better outcome than what is typically seen in patients who receive chemotherapy, Pishvaian says.